Bivalent target-binding bioPROTACs induce potent degradation of oncogenic SHP2
Megan T. Hoffman(Massachusetts Institute of Technology), K. Dane Wittrup(Massachusetts Institute of Technology)
Cited by 11
Related Papers
An engineered protein antagonist of K-Ras/B-Raf interaction
|Scientific Reports|2017|65
Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses
|The Journal of Experimental Medicine|2017|48
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies
|Proceedings of the National Academy of Sciences|2022|31